MedaPhor Group plc
(“MedaPhor” or the “Group” or the “Company”)
Launch of new Point-of-Care Ultrasound simulator
MedaPhor Group plc (AIM: MED), the intelligent ultrasound software and simulation company, announces the launch of its new BodyWorks Eve simulator platform, an ultra-realistic manikin-based simulator to train medical professionals practising Point-of-Care Ultrasound (PoCUS) across emergency medicine and critical care.
First revealed at the International Meeting on Simulation in Healthcare (IMSH) in Los Angeles last month and now launched for general sale, the BodyWorks Eve is believed to be the first hi-fidelity female manikin-based simulator for emergency PoCUS training.
BodyWorks Eve combines the normal and pathological hearts from MedaPhor’s HeartWorks simulator with the complete upper chest to pelvis real patient scans from MedaPhor’s ScanTrainer platform to teach the requirements of the growing PoCUS skills market, as outlined by the International Federation of Emergency Medicine (IFEM). Complete with over 100 real patient ultrasound cases and over 10,000 patient scenario combinations, BodyWorks Eve replicates learning in a real-life emergency or critical care setting, allowing the tutor to control and change the severity and pathology of the patient in real-time.
MedaPhor has partnered with Lifecast Body Simulation (“Lifecast”), who have developed a range of accurate and lifelike ‘bodies’ for medical training, to increase the realism of the BodyWorks Eve simulator. Lifecast supplies the ultra-realistic manikin, which combines with MedaPhor’s intelligent ultrasound simulation technology.
Stuart Gall, Chief Executive Officer at MedaPhor, comments:
“Point-of-Care ultrasound, whilst transforming the front line in emergency medicine and critical care, presents a huge challenge for the global medical industry in terms of upskilling the workforce. BodyWorks Eve is designed to meet these specific PoCUS training requirements and help universities, colleges and hospitals bridge the training gap to deliver positive outcomes for patients.
“We believe Eve can become the gold standard for global PoCUS ultrasound training and is a superb addition to the existing ScanTrainer and HeartWorks simulator range, transforming patient care through comprehensive and flexible learning platforms.”
|MedaPhor Group plc||www.investors.medaphor.com|
|Stuart Gall, CEO|
Ian Whittaker, COO
|Tel: +44 (0)29 2075 6534|
|Cenkos Securities||Tel: +44 (0)20 7397 8900|
|Camilla Hume/Bobbie Hilliam (Nominated Advisor)|
|Michael Johnson / Julian Morse (Corporate Broking)|
|Walbrook PR||Tel: +44 (0)20 7933 8780 or email@example.com|
|Paul McManus / Anna Dunphy||Mob: +44 (0)7980 541 893 / Mob: +44 (0)7876 741 001|
About MedaPhor (www.investors.medaphor.com)
MedaPhor (AIM: MED), the intelligent ultrasound software and simulation company, develops artificial intelligence-based clinical image analysis software tools, augmented reality-based needle guidance software and advanced hi-fidelity haptic and manikin-based training simulators for medical practitioners.
Based in Cardiff and Oxford in the UK and Atlanta in the US, MedaPhor is split into two divisions:
Intelligent Ultrasound Simulation and Training
Focuses on hi-fidelity ultrasound education and training through simulation. Its two main products are the ScanTrainer OBGYN and General Medical simulator training platform and the HeartWorks echocardiography simulator platform. Over 500 MedaPhor simulators have been sold to over 300 medical institutions in over 30 countries around the world.
Intelligent Ultrasound Clinical Support
Focuses on augmented reality and deep-learning based algorithms to make ultrasound machines smarter and more accessible. Products in development include ScanNav which uses machine-learning based algorithms to automatically identify and grade ultrasound images to provide scan assessment and audit of obstetric scanning. NeedleGuide aims to simplify ultrasound-guided needling by using deep learning and augmented reality to provide the user with pathway guidance and automated tracking for a range of medical procedures.
Some products in the pipeline may require US FDA approval, as such this material should be considered informational only and does not constitute an offer to sell, or infer claims or benefits.